AUTH/3190/4/20: Anonymous v Takeda — sponsored type 2 diabetes therapy review service (no breach) | PMCPA Case

📊

Key facts

⌄

Case	AUTH/3190/4/20
Parties	Anonymous v Takeda UK Ltd
Topic	Sponsored therapy review service (type 2 diabetes)
Applicable Code year	2016
Complaint received	30 April 2019
Case completed	14 October 2020
Allegation trigger	Internal third-party email dated 14 August 2018 referencing “integrate client product/therapy priorities” and Takeda service bookings/budget
Medicines mentioned	Actos (pioglitazone), Vipidia (alogliptin), Vipdomet (alogliptin/metformin)
Clauses considered	Clauses 2, 9.1, 12.1, 19.2
Decision	No breach of the Code
Appeal	Yes — complainants appealed no breach of Clause 9.1; appeal unsuccessful

Download the full case report (PDF)

Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI

🎬 Expert Video Walkthrough

🎬

Video walkthrough — coming for members

Subscribe now and get expert video analysis for every case as we publish them.

Subscribe — from £299/yr

📋

What happened

⌄

An anonymous contactable group (GPs, NHS leaders, pharmacists, NHS patients and staff from a named third-party therapy review provider) complained about sponsored therapy review services delivered for multiple pharma companies, including Takeda UK Ltd.
The Takeda-sponsored service related to type 2 diabetes mellitus (T2DM). Takeda marketed Actos (pioglitazone), Vipidia (alogliptin) and Vipdomet (alogliptin/metformin).
The complaint centred on an internal email (14 August 2018) from a senior employee at the third-party provider to its clinical team, which included the phrase about integrating “client product/therapy priorities” into internal resources/schedules and referenced Takeda bookings/budget.
Complainants alleged the email evidenced commercial bias (therapy reviews linked to client products/ROI), lack of transparency, and that this brought the industry into disrepute; they alleged Clause 2 and, via the Authority’s letter, Clauses 2, 9.1, 12.1 and 19.2 were considered.
Takeda said the service was a non-promotional medical and educational good and service (MEGS), designed to improve glycaemic control and delivery of NICE-recommended diabetes care processes; targeted at practices in the bottom quartile for QoF HbA1c <59 mmol/mol achievement; and not contingent on prescribing Takeda products.
Takeda provided written protocols/briefings, described governance (quarterly operational meetings), and said interventions required GP authorisation and were aligned to local/national guidelines and practice-defined treatment pathways.
The Panel reviewed the full email in context and expressed serious concerns about the overall impression of the email across all related cases, but assessed the Takeda service on its own merits.

⚖️

Outcome

⌄

No breach of the Code was ruled.
No breach of Clauses 19.2 and 12.1 (Panel).
No breach of Clause 9.1 (Panel), despite stating Takeda had been “let down” by its third party and expressing serious concerns about the email’s impression.
Given the above, no breach of Clause 2 (Panel).
The complainants appealed the no breach ruling under Clause 9.1; the Appeal Board upheld the Panel’s decision and the appeal was unsuccessful.

🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value

£249/year

Annual — save £99

£29/mo

Monthly

Join Now — Instant Access

AUTH/3190/4/20: Anonymous v Takeda — sponsored type 2 diabetes therapy review service (no breach)

Key facts

What happened

Outcome

Clauses

Unlock the full case analysis

AQP Flagship Path — the complete UK ABPI signatory programme

📰 Weekly PMCPA Case Breakdown